TL;DR — Betaine donates methyl groups through BHMT and reliably lowers homocysteine; performance and longevity implications are less certain. Evidence tierTNiC's A/B/C grading of how strong the human research is behind a compound. Full glossary →: B. Use only when the goal and monitoring plan are clear.
What TMG (Trimethylglycine / Betaine) does
TMG — trimethylglycine, also called betaine — is a methyl donor. Its single best-established job is to hand a methyl group to homocysteine via the enzyme BHMT (betaine-homocysteine methyltransferase), regenerating methionine and reliably lowering blood homocysteine. That makes it a methylation-cycle support compound: relevant to anyone raising homocysteine through high-dose NAD+ precursors (NMN/NR consume methyl groups via NNMT) or with an MTHFR variant. It is also an osmolyte the kidney and liver use for cell-volume regulation. The performance and longevity claims are weaker than the homocysteine effect — hold them to a higher bar.
Primary hallmarks targeted: Epigenetic alterations (methylation supply) · Altered intercellular communication (homocysteine/vascular)
Betaine's homocysteine-lowering effect is well replicated in humans (see the evidence table — PMID 36717385 and related trials). Note the trade-off: a meta-analysis found betaine can modestly raise total/LDL cholesterol at higher doses (PMID 31809615). Homocysteine and lipids are surrogate markers, not healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary → endpoints.
Mechanism and biological context
Homocysteine sits at a branch point in the methylation cycle: it is either re-methylated back to methionine or cleared down the transsulfuration pathway. Betaine feeds the BHMT-dependent remethylation route — a folate-independent path that runs mainly in the liver and kidney — donating one of its three methyl groups to convert homocysteine to methionine. Methionine then becomes SAMe, the universal methyl donor for DNA, histones, neurotransmitters, and phospholipids. This is why betaine is paired with methyl-consuming interventions: high-dose NMN/NR raise methylation demand through NNMT, and betaine helps refill the pool.
| Step | Mechanism | Why it matters |
|---|---|---|
| Methyl donation | Betaine → homocysteine via BHMT | Regenerates methionine (folate-independent route) |
| Methionine → SAMe | Fuels the universal methyl donor | Supports DNA/histone methylation supply |
| Homocysteine clearance | Lowers a vascular risk marker | Rationale for cardiovascular/methylation use |
| Osmolyte role | Cell-volume regulation in kidney/liver | Secondary, non-methylation function |
The mechanism is settled; the open questions are dose-dependent lipid effects and whether homocysteine lowering translates into hard outcomes.
Evidence summary
| Study | Source | Year | Citation |
|---|---|---|---|
| Effects of low-dose B vitamins plus betaine supplementation on lowering homocysteine concentrations among Chinese adults with hyperhomocysteinemia: a randomized, double-blind, controlled preliminary clinical trial. | European journal of nutrition | 2023 | PMID 36717385 |
| Betaine supplementation modulates betaine concentration by methylenetetrahydrofolate reductase genotype, but has no effect on amino acid profile in healthy active males: A randomized placebo-controlled cross-over study. | Nutrition research (New York, N.Y.) | 2024 | PMID 38876040 |
| Betaine Supplementation Moderately Increases Total Cholesterol Levels: A Systematic Review and Meta-Analysis. | Journal of dietary supplements | 2021 | PMID 31809615 |
← Swipe for more columns →
Evidence verdict: Tier B. These records establish that the topic is represented in peer-reviewed literature. Read each design and population before applying its result; adjacent evidence is not interchangeable with a dedicated trial.
Where TMG disappoints
- Lowering homocysteine hasn't moved outcomes. Betaine reliably drops homocysteine — but decades of trials show lowering homocysteine (by any means) generally fails to reduce cardiovascular events. The marker moves; the outcome usually doesn't. - It can raise your cholesterol. A meta-analysis found betaine modestly increases total and LDL cholesterol at higher doses — a real trade-off against a supposed cardiovascular compound. - Standalone value is thin. Its clearest use is as a methyl-donor adjunct to high-dose NMN/NR; if you're not running those and your homocysteine is normal, the case for it is weak.
What would change this grade. TMG is B — a reliable homocysteine/methylation effect with unproven downstream benefit and a lipid trade-off. A trial showing betaine improves a hard endpoint (not just homocysteine) would move it; the disappointing homocysteine-outcome literature keeps it capped.
Is TMG (Trimethylglycine / Betaine) a fit?
Is there a defined goal, a plausible deficiency/indication, and a measurable endpoint?
Consider a time-bounded, monitored trial at the evidence-aligned dose.
Defer it; adding compounds without a decision rule increases cost and interaction risk.
Pregnancy, organ disease, anticoagulation, or interacting medication: obtain clinician review first.
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol
| Parameter | Practical standard |
|---|---|
| Dose | 500-1500 mg/day |
| Timing | with meals |
| Trial length | 8–12 weeks unless the cited indication specifies otherwise |
| Stop rule | Adverse effects, worsening labs, or no meaningful response at review |
A disciplined trial
- Record the exact product, form, and dose.
- Change one major variable at a time.
- Define the endpoint and stop rule before starting.
- Do not extrapolate a disease-population dose to healthy self-experimentation.
Monitoring
| Monitor | When | Why |
|---|---|---|
| Goal-specific symptom or performance metric | Baseline and weekly | Detect a practical response |
| Medication and adverse-effect review | Baseline and each change | Catch interactions early |
| Relevant clinician-selected labs | Baseline and 8–12 weeks | Verify safety and direction |
Question
Vague longevity hope
Review
Indefinite
Question
Specific measurable goal
Review
8–12 week decision point
Safety and red flags
Do not confuse availability with safety
Stop for allergy, persistent gastrointestinal symptoms, neurologic changes, jaundice, unusual bleeding, or any clinically important deterioration.
Evidence in one population does not establish safety in pregnancy, organ impairment, or polypharmacy. Product quality and dose accuracy matter.
Who should skip TMG
- People with elevated LDL or dyslipidemia — betaine can nudge cholesterol upward; watch a lipid panel. - Anyone with normal homocysteine who isn't on high-dose NMN/NR — the standalone rationale is weak. - Pregnancy, or anyone expecting cardiovascular protection from homocysteine-lowering alone — that link hasn't panned out in outcome trials.
Synergies and antagonists
Pairs well with:
| Partner | Integration rationale |
|---|---|
| nmn | High-dose NMN raises methylation demand (NNMT methylates excess nicotinamide); betaine replenishes the methyl pool. The single most-cited reason to pair TMG. |
| nr | Same methyl-consumption logic as NMN — both NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary → precursors draw on SAMe; betaine supports the supply side. |
| glycine | Glycine is a downstream methyl-group acceptor (via GNMT), helping buffer over-methylation when methyl donors run high. |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Lipid/LDL goals | Betaine can raise total and LDL cholesterol at higher doses | Keep the dose modest; monitor a lipid panel |
| Adequate folate/B12 status | The folate-dependent remethylation route already clears homocysteine — betaine is largely redundant when B-vitamins are sufficient | Fix B-vitamin status first; add betaine only if still elevated |
| — | No major drug antagonists at 0.5–1.5 g/day | Otherwise co-stacks cleanly, especially with NAD+ precursors |
Start with the smallest stack that answers the question. SynergyWhen two compounds together produce greater effect than either alone. Full glossary → is a mechanistic hypothesis unless a combination trial demonstrates it.
Personal results template
My TMG (Trimethylglycine / Betaine) results log
| Date | Dose / timing | Primary endpoint | Safety notes | Decision |
|---|---|---|---|---|
| YYYY-MM-DD | Baseline | — | — | Start / defer |
| YYYY-MM-DD | Week 4 | — | — | Continue / adjust / stop |
| YYYY-MM-DD | Week 12 | — | — | Keep / stop |
← Swipe for more columns →
Success rule: a meaningful, repeatable improvement in the preselected endpoint without unacceptable adverse effects or lab movement.
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.